Organization and Description of Business - Additional Information (Details) - USD ($)
$ in Thousands |
3 Months Ended |
|
Mar. 31, 2021 |
Mar. 31, 2020 |
Dec. 31, 2020 |
| Organization and Description of Business [Line Item] |
|
|
|
| Accumulated deficit |
$ 288,081
|
|
$ 260,723
|
| Cash and cash equivalents |
76,963
|
|
$ 28,122
|
| Working capital |
71,500
|
|
|
| Aggregate offering price |
200,000
|
|
|
| Proceeds from issuance of common stock |
60,536
|
$ 0
|
|
| Proceeds from issuance of common stock, deducting underwriting discounts, commissions, and other offering costs |
60,100
|
|
|
| Aggregate offering price, remaining |
$ 132,600
|
|
|
| Common Stock |
|
|
|
| Organization and Description of Business [Line Item] |
|
|
|
| Issuance of common stock in public offering, net (in shares) |
18,400,000
|
|
|
| SFJ Pharmaceuticals X, Ltd. |
|
|
|
| Organization and Description of Business [Line Item] |
|
|
|
| Proceeds from partnership contribution |
$ 27,700
|
|
|
| Equity Distribution Agreement with Citigroup Global Markets Inc. and William Blair & Company, L.L.C. |
|
|
|
| Organization and Description of Business [Line Item] |
|
|
|
| Aggregate offering price |
60,000
|
|
|
| Proceeds from issuance of common stock |
2,900
|
|
|
| Aggregate offering price, remaining |
$ 57,000
|
|
|
| Equity Distribution Agreement with Citigroup Global Markets Inc. and William Blair & Company, L.L.C. | Common Stock |
|
|
|
| Organization and Description of Business [Line Item] |
|
|
|
| Issuance of common stock in public offering, net (in shares) |
561,848
|
|
|